Impact of PET/CT on planning of radiotherapy in head and neck cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 5, 2010, Pages 521-532

  Minn, H ^a   Suilamo, S ^a   Seppala J ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Head and neck neoplasms; Positron emission tomography; Radiotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACCURACY; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; HEAD AND NECK CANCER; HUMAN; IMAGE RECONSTRUCTION; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; PROGNOSIS; REVIEW; TREATMENT PLANNING; TUMOR VOLUME; VOLUMETRY; WORKFLOW;

CELL HYPOXIA; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79251503641     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Grégoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;(Suppl 5):184-6.
2. Zigon G, Berrino F, Gatta G, Sanchez MJ, van Dijk B, Van Eycken E et al. Prognoses for head and neck cancers in Europe diagnosed in 1995-1999: a population-based study. Ann Oncol 2010 (in press).
3. Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin 2008;58:32-53.
4. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-54.
5. Hitt R, Martin P, Hidalgo M. Cetuximab in squamous cell carcinoma of the head and neck. Future Oncol 2006;2:449-57.
6. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27.
7. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
8. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
9. Gillespie MB, Rubinchik S, Hoel B, Sutkowski N. Human papillomavirus and oropharyngeal cancer: what you need to know in 2009. Curr Treat Options Oncol 2009;10:296-307.
10. Lassen P. The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010;95:371-80.
11. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 2009;8:10-6.
12. Mendenhall WM, Riggs CE, Vaysberg M, Amdur RJ, Werning JW. Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma. Head Neck 2010;32:939-45.
13. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-54.
14. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
15. Minn H, Lapela M, Klemi PJ, Grénman R, Leskinen S, Lindholm P et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997;38:1907-11.
16. Gordin A, Golz A, Keidar Z, Daitzchman M, Bar-Shalom R, Israel O. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg 2007;137:130-7.
17. Rodrigues RS, Bozza FA, Christian PE, Hoffman JM, Butterfield RI, Christensen CR et al. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically MO squamous cell carcinoma of the head and neck. J Nucl Med 2009;50:1205-13.
18. Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233:93-100.
19. Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003;57:853-63.
20. Riegel AC, Berson AM, Destian S, Ng T, Tena LB, Mitnick RJ et al. Variability of gross rumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys 2006;65:726-32.
21. Breen SL, Publicover J, De Silva S, Pond G, Brock K, O'Sullivan B et al. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers. Int J Radiat Oncol Biol Phys 2007;68:763-70.
22. 18F- fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100:712-20.
23. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47:755-62.
24. Nahmias C, Carlson ER, Duncan LD, Blodgett TM, Kennedy J, Long MJ et al. Positron emission tomography/computerized tomography (PET/CT) scanning for preoperative staging of patients with oral/head and neck cancer. J Oral Maxillofac Surg 2007;65:2524-35.
25. Connell CA, Corry J, Milner AD, Hogg A, Hicks RJ, Rischin D et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 2007;29:986-95.
26. 18F-FDG PET in suspected recurrent head and neck cancer]. Acta Otorrinolaringol Esp 2008;59:190-7.
27. Kao J, Vu HL, Genden EM, Mocherla B, Park EE, Packer S, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer 2009;115:4586-94.
28. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med 2009;50:1940-7.
29. Malone JP, Gerberi MA, Vasireddy S, Hughes LF, Rao K, Shevlin B et al. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography. Arch Otolaryngol Head Neck Surg 2009; 135:1119-25.
30. 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck 2008;30:471-8.
31. 18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol 2009;45:218-24.
32. Jabour BA, Choi Y, Hoh CK, Rege SD, Soong JC, Lufkin RB et al. Extracranial head and neck: PET imaging with 2-[F-18] fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 1993;186:27-35.
33. Yu H, Caldwell C, Mah K, Mozeg D. Coregistered FDG PET/CT-based textural characterization of head and neck cancer for radiation treatment planning. IEEE Trans Med Imaging 2009;28:374-83.
34. [Cook GJ. Pitfalls in PET/CT interpretation. Q J Nucl Med Mol Imaging 2007;51:235-43.
35. Hwang AB, Bacharach SL, Yom SS, Weinberg VK, Quivey JM, Franc BL et al. Can positron emission tomography (PET) or PET/Computed Tomography (CT) acquired in a nontreatment position be accurately registered to a head-and-neck radiotherapy planning CT? Int J Radiat Oncol Biol Phys 2009;73:578-84.
36. Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol 2009;54:R1-25.
37. Minn H, Gronroos TJ, Komar G, Eskola O, Lehtio K, Tuomela J et al. Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des 2008;14:2932-42.
38. 18) F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008;87:211-6.
39. Seol YM, Kwon BR, Song MK, Choi YJ, Shin HJ, Chung JS et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 2010;49:201-8.
40. Cozzi L, Fogliata A, Bolsi A, Nicolini G, Bernier J. Three-dimensional conformal vs. intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys 2004;58:617-24.
41. Longobardi B, De Martin E, Fiorino C, Dell'oca I, Broggi S, Cattaneo GM et al. Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: equivalence between step-and-shoot and sliding window techniques. Radiother Oncol 2005;77:148-56.
42. Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66:981-91.
43. Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007;25:4873-9.
44. Verbakel WF, Cuijpers JP, Hoffmans D, Bieker M, Slotman BJ, Senan S. Volumetric intensity-modulated arc therapy vs. conventional IMRT in head-and-neck cancer: a comparative planning and dosimetric study. Int J Radiat Oncol Biol Phys 2009;74:252-9.
45. Bertelsen A, Hansen CR, Johansen J, Brink C. Single Arc Volumetric Modulated Arc Therapy of head and neck cancer. Radiother Oncol 2010;95:142-8.
46. Horiot JC, Bontemps P, van den Bogaert W, Le Fur R, van den Weijngaert D, Bolla M et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-21.
47. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933-40.
48. Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer: A review. Crit Rev Oncol Hematol 2010;73:111-25.
49. Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II- clinical results. Int J Radiat Oncol Biol Phys 2004;60:374-87.
50. Guerrero Urbano T, Clark CH, Hansen VN, Adams EJ, A'Hern R, Miles EA et al. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol 2007;85:36-41.
51. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys 2000;46:619-30.
52. Dawson LA, Anzai Y, Marsh L, Martel MK, Paulino A, Ship JA et al. Patterns of local-regional recurrence following parotidsparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2000;46:1117-26.
53. Eisbruch A, Marsh LH, Dawson LA, Bradford CR, Teknos TN, Chepeha DB et al. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004;59:28-42.
54. Thorwarth D, Soukup M, Alber M. Dose painting with IMPT, helical tomotherapy and IMXT: a dosimetric comparison. Radiother Oncol 2008;86:30-4.
55. Madani I, Duthoy W, Derie C, De Gersem W, Boterberg T, Saerens M et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:126-35.
56. Mackay RI, Hendry JH. The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability. Radiother Oncol 1999;50:67-75.
57. Tome WA, Fowler JF. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys 2000;48:593-9.
58. Sovik A, Malinen E, Skogmo HK, Bentzen SM, Bruland OS, Olsen DR. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Int J Radiat Oncol Biol Phys 2007;68:1496-504.
59. Toma-Dasu I, Dasu A, Brahme A. Dose prescription and optimisation based on tumour hypoxia. Acta Oncol 2009;48:1181-92.
60. Grégoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol 2003;69:227-36.
61. Chao KS, Apisarnthanarax S, Ozyigit G. Practical Essentials of Intensity Modulated Radiotherapy. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
62. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med 2008;49(Suppl 2):64S-80S.
63. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007;48:726-35.
64. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 2010;51:866-74.
65. Hentschel M, Appold S, Schreiber A, Abramyuk A, Abolmaali N, Kotzerke J et al. Serial FDG-PET on patients with head and neck cancer: implications for radiation therapy. Int J Radiat Biol 2009;85:796-804.
66. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49 (Suppl 29):129S-48S.
67. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-82.
68. Troost EG, Schinagl DA, Bussink J, Boerman OC, van der Kogel AJ, Oyen WJG et al. Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med 2010; 51:66-76.
69. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944-51.
70. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2008 ;70:2-13.
71. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:541-51.
72. 18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 2006 ;47:256-61.
73. Balogova S, Perie S, Kerrou K, Grahek D, Montravers F, Angelard B et al. Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma. Mol Imaging Biol 2008;10:364-73.
74. 11C]methionine. Int J Radiat Oncol Biol Phys 1994;30:1195-9.
75. 11-C-methionine positron emission tomography for the delineation of the tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison with FDG-PET and CT. Radiother Oncol 2004;71:267-73.
76. 11C-methionine PET. Radiother Oncol 2006; 78:262-9.
77. 18F]BPA: a perspective application to assess tumour extraction of boron in BNCT. Appl Radiat Isot 2009;67(7-8 Suppl):S351-4.
78. Kankaanranta L, Seppala T, Koivunoro H, Saarilahti K, Atula T, Collan J et al. Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:475-82.
79. 18F-FDG PET. Ann Nucl Med 2004;18:409-17.
80. 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging 2010;37:1318-27.
81. 18F-fluoro-2-deoxy-D-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003;48:3077-84.
82. Pantaleo MA, Nannini M, Maleddu A, Fanti S, Ambrosini V, Nanni C et al. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treat Rev 2008;34:103-21.
83. 18F-FDG-PET: implications for staging and radiotherapy planning. Eur J Nucl Med Mol Imaging 2007;34:651-7.
84. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:971-82.
85. Miles KA, Williams RE. Warburg revisited: imaging tumour blood flow and metabolism. Cancer Imaging 2008;8:81-6.